We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
XTL Biopharmaceuticals Ltd | NASDAQ:XTLB | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.022 | 0.92% | 2.422 | 2.20 | 2.70 | 2.49 | 2.405 | 2.46 | 5,253 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2020
011-36000
(Commission File Number)
XTL Biopharmaceuticals Ltd.
(Exact name of Registrant as specified in its charter)
5 Badner St.
Ramat Gan, Israel, 5218102
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On November 25, 2020, XTL Biopharmaceuticals Ltd. (the “Company”) announced that it will hold an Annual General Meeting of Shareholders (the “Annual Meeting”) on December 31, 2020 at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross., 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel. In connection with the Annual Meeting, the Company furnishes the following documents:
1. | A copy of the Notice and Proxy Statement with respect to the Company’s Annual Meeting describing the proposals to be voted upon at the Annual Meeting, the procedure for voting in person or by proxy at the Annual Meeting and various other details related to the Annual Meeting, attached hereto as Exhibit 99.1; |
2. | A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the Annual Meeting without attending in person, attached hereto as Exhibit 99.2; and |
3. | A form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the Annual Meeting without attending in person, attached hereto as Exhibit 99.3. |
1
Exhibit Index
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
XTL BIOPHARMACEUTICALS LTD. | |
Date: November 25, 2020 | /s/ Shlomo Shalev |
Shlomo Shalev Chief Executive Officer |
3
1 Year XTL Biopharmaceuticals Chart |
1 Month XTL Biopharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions